Oliver Bandmann

List of Publications by Year in Descending Order

73 papers	3,880 citations	30 h-index	62 g-index
83 ext. papers	4,722 ext. citations	6.5 avg, IF	5.49 L-index

#	Paper	IF	Citations
73	Plasma neurofilament light levels as a novel biomarker for neurological involve- ment in Wilson disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2022**, 93, A6.2-A6	5.5	
72	PINK1 deficiency impairs adult neurogenesis of dopaminergic neurons. *Scientific Reports*, **2021**, 11, 6617	4.9	10
71	Progress towards therapies for disease modification in Parkinson's disease. *Lancet Neurology, The*, **2021**, 20, 559-572	24.1	13
70	Plasma Neurofilament Light as a Biomarker of Neurological Involvement in Wilson's Disease. *Movement Disorders*, **2021**, 36, 503-508	7	5
69	Wilson's disease: update on pathogenesis, biomarkers and treatments. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**, 92, 1053-1061	5.5	5
68	Cognitive correlates and baseline predictors of future development of visual hallucinations in dementia with Lewy bodies. *Cortex*, **2021**, 142, 74-83	3.8	0
67	Neuroanatomical and cognitive correlates of visual hallucinations in Parkinson's disease and dementia with Lewy bodies: Voxel-based morphometry and neuropsychological meta-analysis. *Neuroscience and Biobehavioral Reviews*, **2021**, 128, 367-382	9	3
66	Targeting mechanisms in cognitive training for neurodegenerative diseases. *Neural Regeneration Research*, **2021**, 16, 500-501	4.5	1
65	Serum FGF-21, GDF-15, and blood mtDNA copy number are not biomarkers of Parkinson disease. *Neurology: Clinical Practice*, **2020**, 10, 40-46	1.7	9
64	Deep phenotyping of peripheral tissue facilitates mechanistic disease stratification in sporadic Parkinson's disease. *Progress in Neurobiology*, **2020**, 187, 101772	10.9	12
63	Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson's disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study. *BMJ Open*, **2020**, 10, e038911	3	6
62	Neurological letter from Bangladesh. *Practical Neurology*, **2020**, 20, 435-445	2.4	
61	Restriction of mitochondrial calcium overload by inactivation renders a neuroprotective effect in zebrafish models of Parkinson's disease. *Biology Open*, **2019**, 8,	2.2	29
60	Reduced habit-driven errors in Parkinson's Disease. *Scientific Reports*, **2019**, 9, 3423	4.9	6
59	Ablation of the pro-inflammatory master regulator miR-155 does not mitigate neuroinflammation or neurodegeneration in a vertebrate model of Gaucher's disease. *Neurobiology of Disease*, **2019**, 127, 563-569	7.5	11
58	The genetic and clinico-pathological profile of early-onset progressive supranuclear palsy. *Movement Disorders*, **2019**, 34, 1307-1314	7	8
57	C9orf72 expansion within astrocytes reduces metabolic flexibility in amyotrophic lateral sclerosis. *Brain*, **2019**, 142, 3771-3790	11.2	29

56	TIGAR inclusion pathology is specific for Lewy body diseases. *Brain Research*, **2019**, 1706, 218-223	3.7	6
55	Animal models of Wilson disease. *Journal of Neurochemistry*, **2018**, 146, 356-373	6	24
54	Porphyria: often discussed but too often missed. *Practical Neurology*, **2018**, 18, 352-358	2.4	21
53	Computer-aided diagnosis for (I)FP-CIT imaging: impact on clinical reporting. *EJNMMI Research*, **2018**, 8, 36	3.6	7
52	The NAD+ Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC and Fly Models of Parkinson's Disease. *Cell Reports*, **2018**, 23, 2976-2988	10.6	141
51	Translational approaches to restoring mitochondrial function in Parkinson's disease. *FEBS Letters*, **2018**, 592, 776-792	3.8	8
50	Parkinson's Disease in Sub-Saharan Africa: A Review of Epidemiology, Genetics and Access to Care. *Journal of Movement Disorders*, **2018**, 11, 53-64	2.9	26
49	The subresolution DaTSCAN phantom: a cost-effective, flexible alternative to traditional phantom technology. *Nuclear Medicine Communications*, **2018**, 39, 268-275	1.6	1
48	Ursodeoxycholic Acid Improves Mitochondrial Function and Redistributes Drp1 in Fibroblasts from Patients with Either Sporadic or Familial Alzheimer's Disease. *Journal of Molecular Biology*, **2018**, 430, 3942-3953	6.5	35
47	Prodromal Parkinsonism and Neurodegenerative Risk Stratification in REM Sleep Behavior Disorder. *Sleep*, **2017**, 40,	1.1	93
46	Epidemiology and introduction to the clinical presentation of Wilson disease. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2017**, 142, 7-17	3	26
45	Inhibition of the mitochondrial calcium uniporter rescues dopaminergic neurons in pink1 zebrafish. *European Journal of Neuroscience*, **2017**, 45, 528-535	3.5	57
44	Structural and Functional Neuroimaging of Visual Hallucinations in Lewy Body Disease: A Systematic Literature Review. *Brain Sciences*, **2017**, 7,	3.4	19
43	Glucocerebrosidase 1 deficient Danio rerio mirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death. *Human Molecular Genetics*, **2015**, 24, 6640-52	5.6	72
42	UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2(G2019S) carriers and in vivo. *Neurology*, **2015**, 85, 846-52	6.5	76
41	Deep learning for automatic cell detection in wide-field microscopy zebrafish images **2015**,		30
40	Wilson's disease and other neurological copper disorders. *Lancet Neurology, The*, **2015**, 14, 103-13	24.1	449
39	pH-sensitive tubular polymersomes: formation and applications in cellular delivery. *ACS Nano*, **2014**, 8, 4650-61	16.7	78

38	The documentation of consent and disclosure of neurogenetic testing outside clinical genetics. *Neurogenetics*, **2014**, 15, 19-21	3	1
37	Three-Dimensional Deconvolution of Wide Field Microscopy with Sparse Priors: Application to Zebrafish Imagery **2014**,		2
36	The common PARK8 mutation LRRK2G□□□S is not a risk factor for breast cancer in the absence of Parkinson's disease. *Journal of Neurology*, **2013**, 260, 2177-8	5.5	5
35	A genetic study of Wilson's disease in the United Kingdom. *Brain*, **2013**, 136, 1476-87	11.2	219
34	Heterozygous mutations in the FGF8, SHH and nodal/transforming growth factor beta pathways do not confer increased dopaminergic neuron vulnerability--a zebrafish study. *Neuroscience Letters*, **2013**, 532, 55-8	3.3	1
33	Delayed toxic-hypoxic encephalopathy. *Practical Neurology*, **2013**, 13, 114-9	2.4	6
32	Transglutaminase 6 antibodies in the diagnosis of gluten ataxia. *Neurology*, **2013**, 80, 1740-5	6.5	107
31	C9ORF72 expansions, parkinsonism, and Parkinson disease: a clinicopathologic study. *Neurology*, **2013**, 81, 808-11	6.5	49
30	TigarB causes mitochondrial dysfunction and neuronal loss in PINK1 deficiency. *Annals of Neurology* , **2013**, 74, 837-47	9.4	50
29	Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease. *Brain*, **2013**, 136, 3038-50	11.2	84
28	Neuronal dark matter: the emerging role of microRNAs in neurodegeneration. *Frontiers in Cellular Neuroscience*, **2013**, 7, 178	6.1	135
27	Prolonged generalized dystonia after chronic cerebellar application of kainic acid. *Brain Research*, **2012**, 1464, 82-8	3.7	26
26	The Prevalence of Juvenile Huntington's Disease: A Review of the Literature and Meta-Analysis. *PLOS Currents*, **2012**, 4, e4f8606b742ef3		73
25	The influence of the zebrafish genetic background on Parkinson's disease-related aspects. *Zebrafish*, **2011**, 8, 103-8	2	9
24	Parkinson's disease: insights from pathways. *Human Molecular Genetics*, **2010**, 19, R21-7	5.6	137
23	Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. *Neurology*, **2010**, 75, 2017-20	6.5	214
22	Genetic zebrafish models of neurodegenerative diseases. *Neurobiology of Disease*, **2010**, 40, 58-65	7.5	87
21	Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (Danio rerio). *Brain*, **2009**, 132, 1613-23	11.2	128

20	Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. *Nature Neuroscience*, **2009**, 12, 1129-35	25.5	253
19	Zebrafish as a new animal model for movement disorders. *Journal of Neurochemistry*, **2008**, 106, 1991-7	6	99
18	Complicated autosomal recessive hereditary spastic paraplegia: a complex picture is emerging. *Neurology*, **2008**, 70, 1375-6	6.5	7
17	Evaluation of the Unified Wilson's Disease Rating Scale (UWDRS) in German patients with treated Wilson's disease. *Movement Disorders*, **2008**, 23, 54-62	7	71
16	Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts. *Annals of Neurology*, **2008**, 64, 555-65	9.4	280
15	p53-dependent neuronal cell death in a DJ-1-deficient zebrafish model of Parkinson's disease. *Journal of Neurochemistry*, **2007**, 100, 1626-35	6	148
14	Brain-derived neurotrophic factor: a genetic risk factor for obsessive-compulsive disorder and Tourette syndrome?. *Movement Disorders*, **2006**, 21, 881-3	7	16
13	Prevalence of the H1069Q mutation in ATP7B in discordant pairs with early-onset Parkinson's disease. *Movement Disorders*, **2006**, 21, 1789-90	7	5
12	Epsilon-sarcoglycan is not involved in sporadic Gilles de la Tourette syndrome. *Neurogenetics*, **2005**, 6, 55-6	3	2
11	Neurodegenerative disorders: Parkinson's disease and Huntington's disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2005**, 76, 1058-63	5.5	59
10	Normal dopaminergic and serotonergic metabolites in cerebrospinal fluid and blood of restless legs syndrome patients. *Movement Disorders*, **2004**, 19, 192-6	7	54
9	Dopamine receptor gene polymorphisms in Parkinson's disease patients reporting "sleep attacks". *Movement Disorders*, **2004**, 19, 1279-84	7	45
8	Slow N-acetyltransferase 2 status leads to enhanced intrastriatal dopamine depletion in 6-hydroxydopamine-lesioned rats. *Experimental Neurology*, **2004**, 187, 199-202	5.7	8
7	Lack of association between the interleukin-1 alpha (-889) polymorphism and early-onset Parkinson's disease. *Neuroscience Letters*, **2004**, 359, 195-7	3.3	19
6	HLA-DRB genotyping in Gilles de la Tourette patients and their parents **2003**, 119B, 60-4		10
5	Detailed genotyping demonstrates association between the slow acetylator genotype for N-acetyltransferase 2 (NAT2) and familial Parkinson's disease. *Movement Disorders*, **2000**, 15, 30-5	7	32
4	Genetic aspects of Parkinson's disease. *Movement Disorders*, **1998**, 13, 203-11	7	35
3	Mental disorders in movement disorders. *Current Opinion in Psychiatry*, **1998**, 11, 315-319	4.9	1

2	The GTP-cyclohydrolase I gene in atypical parkinsonian patients: a clinico-genetic study. *Journal of the Neurological Sciences*, **1996**, 141, 27-32	3.2	18
1	Apo E genotypes in multiple sclerosis, Parkinson's disease, schwannomas and late-onset Alzheimer's disease. *Molecular and Cellular Probes*, **1994**, 8, 519-25	3.3	54